Table 4b. Number of patients with any treatment-related haematological toxicity grade 3 or 4 according to the NCI-common toxicity criteria (CTC) at cycle 1 and post cycle 1.

Dose levela	350/6		500/6		600/6		600/5		All
Number of evaluable patients	4		3		4		5		16
CTC grade	3	4	3	4	3	4	3	4	3	4
Cycle 1
Platelets	0	0	1	0	1	2	3	1	5 (31%)	3 (19%)
Neutrophils	0	0	0	0	1	1	0	1	1 (6%)	2 (13%)
Leucocytes	0	0	0	0	1	0	1	1	2 (13%)	1 (6%)
Lymphocytes	0	0	0	0	0	0	1	0	1 (6%)	0 (0%)
Haemoglobin	0	0	0	0	0	1	2	0	2 (13%)	1 (6%)
Post cycle 1
Platelets	3	0	2	1	1	2	4	1	10 (63%)	4 (25%)
Neutrophils	2	0	2	1	3	2	2	4	9 (56%)	7 (44%)
Leucocytes	2	0	1	0	1	0	4	2	8 (50%)	2 (13%)
Lymphocytes	1	0	0	0	0	0	3	0	4 (25%)	0 (0%)
Haemoglobin	2	0	1	0	2	0	2	0	7 (44%)	0 (0%)

^aIndisulam (mg m⁻²)/carboplatin (mg min ml⁻¹).